During the II National Congress of Pediatric Neurologists, held from March 20-22 in Moscow, Sotex and Rafarma showcased their portfolio of neurological drugs designed for treating cognitive impairment, asthenia, and anxiety disorders in children. The event, held on March 20-22 in Moscow and became a platform for discussing key issues and modern achievements in pediatric neurology.
It brought together over 1,500 healthcare professionals, including neurologists, pediatricians, neurosurgeons, speech therapists, geneticists, and healthcare organizers, aiming to unite experts in the field of child health, facilitate experience sharing, and discuss current challenges and innovative solutions in the diagnosis, treatment, and prevention of pediatric neurological diseases.
The scientific program spanned a wide array of topics, including the role of Sotex and Rafarma’s medications in addressing various neurological conditions. Leonid Chutko, Head of the Behavioral Neurology Center at the N. P. Bekhtereva Institute of the Human Brain of the Russian Academy of Sciences, presented Cogitum’s potential in treating asthenic disorders associated with hyperactivity in children.
Svetlana Nemkova, Doctor of Sciences in Medicine, a professor at the Department of Neurology, Neurosurgery, and Medical Genetics named after Academician L. O. Badalyan at Pirogov Russian National Research Medical University, discussed modern corrective methods for addressing cognitive and asthenic disorders in children with cerebral palsy, highlighting clinical studies that demonstrated the positive effects of Cereton and Cogitum on cognitive functions.
Dina Gainetdinova, a professor at Kazan State Medical University and an academician of the Academy of Sciences of the Republic of Tatarstan, emphasized the diverse types of cognitive impairments in children and identified perinatal factors influencing cognitive development. She reported findings from a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of Cereton, available in oral solution and capsules, for children recovering from traumatic brain injuries and hemorrhagic strokes.
Yuri Nesterovsky, Candidate of Sciences in Medicine, Associate Professor addressed the issue of school maladaptation among adolescents, linking headaches to cognitive impairments in school-age children. He provided insights from a clinical study on the effectiveness of Cereton in adolescents experiencing mild to moderate cognitive impairments due to residual organic brain conditions.
At the Sotex exhibition stand, attendees explored new scientific publications and methodological manuals detailing clinical trial data on Cereton, Cogitum, and Anvifen for the treatment of cognitive, asthenic, and anxiety disorders in children.
